Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Cidara Therapeutics (NASDAQ: CDTX) announced that its President and CEO, Jeffrey Stein, Ph.D., will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 4:40 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (NASDAQ: CDTX) announced that its President and CEO, Jeffrey Stein, Ph.D., will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 4:40 PM ET. The event will feature a live audio webcast available on the company's website. Cidara focuses on developing long-acting therapeutics for serious fungal and viral infections, highlighting its lead antifungal candidate, rezafungin, and its antiviral platform, Cloudbreak®.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was -0.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021.
| Panel Information: | |
| Date: | Wednesday, August 11, 2021 |
| Time: | 4:40 PM ET |
| Webcast: | A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com. |
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.